On the role of different age groups during pertussis epidemics in California, 2010 and 2014.
Age groups
pertussis
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
8
5
2019
pubmed:
8
5
2019
medline:
28
3
2020
Statut:
ppublish
Résumé
There is limited information on the roles of different age groups in propagating pertussis outbreaks, and the temporal changes in those roles since the introduction of acellular pertussis vaccines. The relative roles of different age groups in propagating the 2010 and the 2014 pertussis epidemics in California were evaluated using the relative risk (RR) statistic that measures the change in the group's proportion among all detected cases before vs. after the epidemic peak. For the 2010-11 epidemic, evidence for a predominant transmission age group was weak, with the largest RR estimates being 1.26 (95% CI 1.08-1.46) (aged 11-13 years); 1.19 (1.01-1.4) (aged 9-10 years); 1.17 (0.86-1.59) (aged 14-15 years); 1.12 (0.86-1.46) (aged 16-19 years) and 1.1 (0.89-1.36) (aged 7-8 years). The 2014 epidemic showed a strong signal of the role of older adolescents, with the highest RR estimate being in those aged 14-15 years (RR = 1.83, 1.61-2.07), followed by adolescents aged 16-19 years (RR = 1.41, 1.24-1.61) and 11-13 years (RR = 1.26, 1.12-1.41), with lower RR estimates in other age groups. As the time following introduction of acellular pertussis vaccines in California progressed, older adolescents played an increasing role in transmission during the major pertussis outbreaks. Booster pertussis vaccination for older adolescents with vaccines effective against pertussis transmission should be considered with the aim of mitigating future pertussis epidemics in the community.
Identifiants
pubmed: 31063110
pii: S0950268819000761
doi: 10.1017/S0950268819000761
pmc: PMC6518560
doi:
Substances chimiques
Pertussis Vaccine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e184Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Références
Curr Opin Infect Dis. 2009 Jun;22(3):215-23
pubmed: 19395958
Infect Genet Evol. 2010 Jan;10(1):36-49
pubmed: 19879977
Vaccine. 2010 Apr 26;28(19):3285-90
pubmed: 20226250
J Pediatr. 2012 Dec;161(6):1091-6
pubmed: 22819634
JAMA. 2012 Aug 1;308(5):454-6
pubmed: 22851107
N Engl J Med. 2012 Sep 13;367(11):1012-9
pubmed: 22970945
JAMA. 2012 Nov 28;308(20):2126-32
pubmed: 23188029
Epidemiol Infect. 2014 Apr;142(4):672-84
pubmed: 23324361
Clin Infect Dis. 2013 May;56(9):1248-54
pubmed: 23487373
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787-92
pubmed: 24277828
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E716-7
pubmed: 24516173
J Infect Dis. 2014 Apr 1;209(7):978-81
pubmed: 24626532
Clin Infect Dis. 2014 Jul 15;59(2):261-3
pubmed: 24748523
J Infect Dis. 2014 Sep 15;210(6):942-53
pubmed: 24903664
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
MMWR Morb Mortal Wkly Rep. 2014 Dec 5;63(48):1129-32
pubmed: 25474033
Pediatrics. 2015 Jun;135(6):981-9
pubmed: 25941309
Sci Rep. 2015 Aug 17;5:13182
pubmed: 26278132
Proc Biol Sci. 2016 Jan 13;283(1822):null
pubmed: 26763701
Pediatrics. 2016 May;137(5):
pubmed: 27244813
Epidemiology. 2017 Jan;28(1):136-144
pubmed: 27748685
Pediatr Infect Dis J. 2018 Apr;37(4):324-328
pubmed: 29088031
J Infect Dis. 2018 Jan 4;217(2):238-244
pubmed: 29112722
Vaccine. 2018 Feb 21;36(9):1160-1166
pubmed: 29395520
Open Forum Infect Dis. 2018 Apr 16;5(5):ofy082
pubmed: 29942818